Nicole LaBrosse - HALO / Halozyme Therapeutics, Inc. - Insider Trade Report

Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Nicole LaBrosse in HALO / Halozyme Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Nicole LaBrosse in HALO / Halozyme Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2023-02-16	2,525	49.2600	2,525	49.2600	124,382	81	30.2800	-47,924	-38.53
2022-11-15	4,635	53.8200	4,635	53.8200	249,456
2022-11-15	365	53.6900	365	53.6900	19,597

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Transaction History